Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IB-001 in Healthy Participants and Participants With Chronic Hepatitis B
NCT07389044Phase 1Recruiting
- Sponsor
- IntegerBio
- Start
- Feb 2026
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of IB-001 in Chronic Hepatitis B (CHB) (3 arms), sponsored by IntegerBio. Primary endpoints: Incidence and Severity of Treatment-Emergent Adverse Events at Day 64, Number of Participants with Adverse Events by Severity at Day 64 and 4 more. Started Feb 2026; status: recruiting.
02
Drugs
IB-001
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07389044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07389044.